|
|
|
| Effect and safety of different maintenance doses of Caffeine Citrate in the treatment of premature infants with gestational age ＜34 weeks with apnea |
| HUANG Yao |
| Department of Neonatology, Yingtan People′ Hospital, Jiangxi Province, Yingtan 335000, China |
|
|
|
|
Abstract Objective To explore the effect and safety of different maintenance doses of Caffeine Citrate in the treatment of premature infants with gestational age ＜34 weeks with apnea.Methods A total of 80 premature infants with apnea less than 34 weeks of gestational age admitted to Yingtan People′ Hospital from February 2019 to February 2020 were selected as the research objects and divided into the control group and the observation group according to the random number table method, with 40 patients in each group.Both groups were treated with Caffeine Citrate as a therapeutic agent.The dosage of the control group was 5 mg/(kg·d), and the dose of the observation group was 10 mg/(kg·d).The total effective rate, treatment time, number of apnea at different stages and the probability of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was higher than that in the control group, and the difference was statistically significant (P＜0.05).The mechanical ventilation time, low-flow oxygen ventilation time and hospital stay time of the observation group were shorter than those of the control group, and the differences were statistically significant (P＜0.05).The number of apnea after 24, 48, 72 hours in the observation group was fewer than that in the control group, and the differences were statistically significant (P＜0.05).The total incidence of adverse reactions of the observation group was lower than that of the control group, and the difference was statistically significant (P＜0.05).Conclusion The maintenance dose of 10 mg/(kg·d) of Caffeine Citrate is more effective in the treatment of premature infants with apnea ＜34 weeks of gestational age and less adverse reactions.
|
|
|
|
|
|
| [1] |
李晓玲.阻塞性睡眠呼吸暂停综合征患者发生心脏事件的临床分析[J].中外医学研究，2018，16（8）：143-145.
|
| [2] |
侯小丽，吴述光，郭悦鹏.艾塞那肽治疗肥胖2型糖尿病并发阻塞性睡眠呼吸暂停综合征疗效观察[J].新乡医学院学报，2018，35（1）：50-53.
|
| [3] |
彭丽.阻塞性睡眠呼吸暂停综合征伴高血压的治疗研究进展[J].现代医药卫生，2018，34（9）：1371-1374.
|
| [4] |
曾云燕，杨林.枸橼酸咖啡因治疗早产儿呼吸暂停疗效分析[J].中国妇幼健康研究，2018，29（3）：148-149.
|
| [5] |
黄荔涵，洪昆峣，吴倩倩.枸橼酸咖啡因与氨茶碱治疗早产儿呼吸暂停的疗效对比[J].中国妇幼保健，2018，33（11）：2507-2509.
|
| [6] |
林忠辉，马艳杰，杨丽.美国睡眠医学会2014年《儿童阻塞性睡眠呼吸暂停诊断标准》[J].中国医学文摘（耳鼻咽喉科学），2015，30（4）：212-213.
|
| [7] |
何权瀛，王莞尔.阻塞性睡眠呼吸暂停低通气综合征诊治指南（基层版）[J].中国呼吸与危重监护杂志，2015，14（4）：398-405.
|
| [8] |
龙小红，龙文香，周福根.早产儿呼吸暂停的药物干预与管理[J].当代医学，2018，24（6）：180-182.
|
| [9] |
陆璐，王迎.湿化高流量鼻导管通气在早产儿呼吸系统疾病临床应用研究进展[J].医学综述，2019，25（6），1208-1211，1216.
|
| [10] |
郭开扬，谭清，黎媛嫦.小胎龄早产儿出现呼吸暂停相关因素分析[J].吉林医学，2018，39（8）：1433-1434.
|
| [11] |
谢露，张铮，孙立平，等.晚期早产儿呼吸窘迫综合征与早产儿呼吸暂停的相关性研究[J].中国妇幼保健，2018，33（13）：113-116.
|
| [12] |
刘雅竹，陈亚丹，李婷婷，等.不同剂量枸橼酸咖啡因用于早产儿呼吸暂停的疗效和安全性系统评价[J].中国医院药学杂志，2018，38（2）：173-178.
|
| [13] |
张霄，张海涛，吕勇，等.不同维持剂量枸橼酸咖啡因治疗极低出生体重早产儿呼吸暂停的前瞻性随机对照研究[J].中国当代儿科杂志，2019，21（6）：558-561.
|
| [14] |
刘洪杰,朱艳萍.枸橼酸咖啡因在新生儿期的临床应用进展[J].中国医药导报，2015，12（33）：69-73.
|
| [15] |
周建福.不同剂量枸橼酸咖啡因治疗早产儿原发性呼吸暂停的临床分析[J].中外医学研究，2019，17（10）：63-64.
|
| [16] |
肖景霞，张成云，安丽花.枸橼酸咖啡因应用于极早早产儿的临床疗效分析[J].中国中西医结合儿科学，2019，11（1）：69-71.
|
|
|
|
